Glycemic variability: The third component of the dysglycemia in diabetes. Is it important? how to measure it?

Journal of Diabetes Science and Technology

Volumn 2, Issue 6, 2008, Pages 1094-1100

  Monnier, Louis ^a   Colette, Claude ^a   Owens, David R ^b  

^a UNIV MONTPELLIER   (France)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Glycemic assessment; Glycemic importance; Glycemic variability

Indexed keywords

EID: 77954804860     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200618     Document Type: Review

References (36)

1. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5(4):294-315.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
3. Stratton IM, Adler AL, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
4. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436-72.
5. Gorus F, Mathieu C, Gerlo E. How should HbAlc measurements be reported? Diabetologia. 2006;49(1):7-10.
6. UK Prospective Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
7. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up. Diabetologia. 1996;39(12):1577-83.
8. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications. Arch Int Med. 2004;164(19):2090-5.
9. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813-9.
10. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008;31 Suppl 2:S150-4.
11. Monnier L, Colette C, Owens DR. Type 2 diabetes: a wellcharacterised but suboptimally controlled disease. Can we bridge the divide? Diabetes Metab. 2008;34(3):207-16.
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20.
13. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25(8):1439-43.
14. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.
15. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349-54.
16. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29(7):1486-90.
17. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, De Vries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-90.
18. Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res. 2007;39(9):683
19. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care. 1987;10(2):225-37.
20. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644-55.
21. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetics. Acta Med Scand. 1965;177:95-102.
22. McDonnell CM, Donath SM, Vidmar SI, Werther G A, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253-63.
23. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433-8.
24. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8(5):342-8.
25. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008;10(3):149-59.
26. International Diabetes Federation. Guideline for management of postmeal glucose. Brussels: IDF; 2007, p. 1-27.
27. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J, Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis. 2008;18(4):S17-33.
28. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med. 1992;327(10):707
29. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263-9.
30. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31 Suppl l: S12-54.
31. Buckingham B, Block J, Wilson DM. Continuous glucose monitoring. Curr Opin Endocrinol Diabetes. 2005;12(4):273-9.
32. Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab. 2007;33(4):247-52.
33. Monnier L, Colette C, Lapinski H, Boniface H. Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab. 2004;30(2):113-9.
34. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin Ale. JAMA. 2006;295(14):1688-97.
35. Riddle MC, Rosenstock J, Gerich J on behalf of the Insulin Glargine 4002 Study Investigators. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-6.
36. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab. 2006;32(1):7-13.